Growth hormone–releasing hormone receptor (GHRH-R) shows promise as a molecular target for gastric cancer therapies, according to investigators.
“The GHRH receptor is both a biomarker that can confirm prognosis and a therapeutic target,” Andrew V. Schally, PhD, MDhc, DSchc, a Nobel Prize laureate, a scientist at the University of Miami Sylvester Comprehensive Cancer Center and a professor of pathology at the University of Miami Miller School of Medicine, commented in a news